Evinacumab(anti-ANGPTL3) | Read Reviews & Product Use Citations

Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Selleck's Evinacumab(anti-ANGPTL3) has been cited by 0 Publication

1 Customer Review

Purity & Quality Control

Batch: Purity: 98% Protein concentration: 6.5mg/ml Endotoxin Level: ＜1EU/mg

98

Biological Activity

Description	Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Product Details

CAS No.	1446419-85-7
Molecular Weight	150 kDa
Isotype	human IGg1, λ
Application	Evinacumab(anti-ANGPTL3)
Source	CHO
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field